ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Amantadine use in the French prospective NS-Park cohort

  • 期刊论文

  • 发表日期：

    2024年4月5日

查看全文
  • Margherita Fabbri,
  • Vanessa Rousseau,
  • Jean-Christophe Corvol,
  • Agnès Sommet,
  • Florence Tubach,
  • Yann De Rycke,
  • Nathalie Bertille,
  • Yajiththa Selvarasa,
  • Stephanie Carvalho,
  • Véronique Chaigneau,
  • Christine Brefel-Courbon,
  • Fabienne Ory-Magne,
  • Samuel Tessier,
  • Melissa Tir,
  • Matthieu Bereau,
  • Wassilios G. Meissner,
  • Claire Thiriez,
  • Ana Marques,
  • Philippe Remy,
  • Vincent Schneider,
  • Elena Moro,
  • Luc Defebvre,
  • Jean Luc Houeto,
  • Stephane Prange,
  • Alexandre Eusebio,
  • Christian Geny,
  • Solène Frismand,
  • Philippe Damier,
  • Caroline Giordana Reuther,
  • Giovanni Castelnovo,
  • Isabelle Benatru,
  • Anne Doe De Maindreville,
  • Sophie Drapier,
  • David Maltête,
  • Ouhaid Lagha-Boukbiza,
  • Olivier Rascol,
  • Mickael Aubignat,
  • Eloi Magnin,
  • Pr Pierre Burbaud,
  • Pr Dominique Guehl,
  • Alexandra Foubert-Samier,
  • Brice Laurens,
  • Thomas Boraud,
  • Sylvain Vergnet,
  • David Bendetowicz,
  • Thomas Palpacuer,
  • Bérengère Debilly,
  • Philippe Derost,
  • Charlotte Beal,
  • Hayet Salhi,
  • Alice Dormeuil,
  • Aimée Petit,
  • Alban Gravier,
  • Gwendoline Dupont,
  • Lucie Garnier,
  • Valérie Fraix,
  • Anna Castrioto,
  • Sara Meoni,
  • Nicolas Carriere,
  • Teodor Danaila,
  • Chloé Laurencin,
  • Stéphane Thobois,
  • Jean-Philippe Azulay,
  • Frédérique Fluchere,
  • Mahmoud Charif,
  • Marie-Christine Picot,
  • Lucie Hopes,
  • Anne-Gaelle Corbille,
  • Tiphaine Rouaud,
  • Pascal Derkinderen,
  • Cosmin Alecu,
  • Charlotte Heraud,
  • Marie De Verdal,
  • Bertrand Degos,
  • Graziella Mangone,
  • Sara Sambin,
  • Aymeric Lanore,
  • Thomas Courtin,
  • Louise-Laure Mariani,
  • David Bendetowicz,
  • Fouad Khoury,
  • Poornima Menon,
  • Florence Cormier-Dequaire,
  • Emmanuel Flamand-Roze,
  • David Grabli,
  • Elodie Hainque,
  • Marie Vidhaillet,
  • Aurélie Meneret,
  • Cécile Delorme,
  • Cendrine Foucard,
  • Florian Von Raison,
  • Alexis Elbaz,
  • Andreas Hartmann,
  • Vincent Leclercq,
  • Solène Ansquer,
  • Frederique Leh,
  • Marion Leclercq,
  • Guillaume Costentin,
  • Lagha Boukbiza,
  • Christine Brefel Courbon,
  • Clemence Leung,
  • Hélène Catala,
  • Astrid Causel,
  • Emilie Gaiffe,
  • Sandrine Dupouy,
  • Sandrine Villars,
  • Wei-Ho Lai,
  • Rachida Bari,
  • Damien Chevanne,
  • Elodie Durand,
  • Isabelle Rieu,
  • Stephane Bernard,
  • Corinne Garsault,
  • Noel Boudjema,
  • Pascale Grebent,
  • Andrea Kistner,
  • Pierre Pelissier,
  • Valérie Santraine,
  • Thomas Gaudin,
  • Pierre Boutet,
  • Catherine Caire,
  • Manel Nouira,
  • Claudia Verna,
  • Amory Jardel,
  • Salomé Puisieux,
  • Guillemette Clement,
  • Lili Le Monnier,
  • Régis Frenais,
  • Séverine Le Dily,
  • Rachel Chaigneau,
  • Vanessa Ferrier,
  • Elodie David,
  • Leslie Fra,
  • Elsa Foucaran,
  • Carole Dongmo-Kenfack,
  • Florence Beauzor,
  • Mickael Le,
  • Sonia Messar,
  • Sophie Liot,
  • Emilie Rabois,
  • Margaux Bonnaire-Verdier,
  • Françoise Kestens,
  • Rozenn Gourhan,
  • Sandra Lopez-Alfaro,
  • Jean-François Houvenaghel,
  • Mélanie Alexandre,
  • Christine Bourdonnais,
  • Linda Vernon,
  • Ahmed Boumediene,
  • Céline Julie,
  • Aurette Lobstein,
  • Nadine Longato,
  • Marie-Pierre Mitterle,
  • Clélie Philips,
  • Hugo Rummel,
  • Stéphanie Bras,
  • Estelle Harroch,
  • Claudia Gillet

摘要

Objective

To assess amantadine use and associated factors in the patients with Parkinson’s disease (PD).

Background

Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical practice to treat “levodopa-induced dyskinesia (LIDs). Its use varies according to countries and PD stages. The prospective NS-Park cohort collects features of PD patients followed by 26 French PD Expert Centres.

Methods

Variables used for the analyses included demographics, motor and non-motor PD symptoms and motor complications [motor fluctuations (MFs), LIDs)], antiparkinsonian pharmacological classes and levodopa equivalent daily dose (LEDD). We evaluated: (i) prevalence of amantadine use and compared clinical features of amantadine users vs. non-users (cross-sectional analysis); (ii) factors associated with amantadine initiation (longitudinal analysis); (iii) amantadine effect on LIDs, MFs, apathy, impulse control disorders and freezing of gait (Fog) (longitudinal analysis).

Results

Amantadine use prevalence was 12.6% (1,585/12,542, median dose = 200 mg). Amantadine users were significantly younger, with longer and more severe PD symptoms, greater LEDD and more frequent use of device-aided/surgical treatment. Factors independently associated with amantadine initiation were younger age, longer PD duration, more frequent LIDs, MFs and FoG, higher LEDD and better cognitive function. 9 of the 658 patients on amantadine had stopped it at the following visit, after 12–18 months (1.3%). New users of amantadine presented a higher improvement in LIDs and MF compared to amantadine never users.

Conclusions

About 12% of PD patients within the French NS-Park cohort used amantadine, mostly those with younger age and more severe PD. Amantadine initiation was associated with a subsequent reduction in LIDs and MFs.